Definitely, but there is still a lot of investigations that are ongoing in this space and we’re looking forward to seeing the results of those studies. But it’s important to note that Belzutifan is one of the drugs that relies on one of the most important and canonical pathways that is seen in clear cell RCC, as opposed to non-clear cell RCC, which is, you know, the VEGF-HIF2 axis...
Definitely, but there is still a lot of investigations that are ongoing in this space and we’re looking forward to seeing the results of those studies. But it’s important to note that Belzutifan is one of the drugs that relies on one of the most important and canonical pathways that is seen in clear cell RCC, as opposed to non-clear cell RCC, which is, you know, the VEGF-HIF2 axis. And in this setting, VEGF-HIF2 inhibitors present with promising activity in patients with clear cell RCC. It’s important definitely to try to identify biomarkers from the clinical and translational standpoint which could be potentially pointing out extreme responders or poor responders and definitely more investigation will be upcoming about this.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
